Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
Rhea-AI Summary
4D Molecular Therapeutics (NASDAQ:FDMT) is under investigation by The Schall Law Firm for potential securities law violations. The investigation centers on whether the company made false or misleading statements to investors. Despite the company presenting positive interim results from its Phase 2 PRISM study on Intravitreal 4D-150 on July 17, 2024, the stock experienced a significant decline of over 35.8% in afternoon trading on the same day. The law firm is encouraging affected shareholders to participate in the investigation.
Positive
- None.
Negative
- Stock price dropped 35.8% following Phase 2 PRISM study results announcement
- Company faces securities law violation investigation
- Potential misleading statements to investors regarding clinical trial results
News Market Reaction 1 Alert
On the day this news was published, FDMT declined 0.73%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
LOS ANGELES, CA / ACCESSWIRE / October 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. 4D Molecular Therapeutics released the interim results of its Phase 2 PRISM study on Intravitreal 4D-150 on July 17, 2024. Despite the Company billing the results as positive, the stock fell by more than
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
SOURCE: The Schall Law Firm
View the original press release on accesswire.com
FAQ
Why did 4D Molecular Therapeutics (FDMT) stock drop 35.8% on July 17, 2024?
What is the investigation against 4D Molecular Therapeutics (FDMT) about?
When did The Schall Law Firm announce its investigation of FDMT?
